跳至主要内容
临床试验/NCT01044316
NCT01044316已完成3 期

A Phase III Observer-Blind, Randomized, Controlled, Single-Coordinating Center Pediatric Study in China Comparing Two Doses of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Vaccine Versus a Tetanus Toxoid-Conjugated Vaccine Using a Local Dosing Regimen in Infants

Novartis Vaccines1 个研究点 分布在 1 个国家目标入组 670 人开始时间: 2010年4月最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
670
试验地点
1
主要终点
Anti-PRP antibody levels at day 31 post last vaccination

研究概览

简要总结

This study will evaluate the safety and efficacy of two doses of two commercially available vaccines used to prevent Haemophilus influenzae type b infections in children 6-12 months of age.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
6 Months 至 12 Months(Child)
性别
All
接受健康志愿者

入选标准

  • Infants 6-12 months of age.

排除标准

  • Prior Hib vaccine administration.
  • History of serious reaction(s) following vaccination.
  • Any vaccination within 14 days of study vaccination.
  • Known or suspected immune impairment.
  • For additional entry criteria please refer to the protocol.

结局指标

主要结局

Anti-PRP antibody levels at day 31 post last vaccination

时间窗: 30 days after last vaccination

次要结局

  • Solicited local and systemic reactions, AEs, and SAEs(30 days post last vaccination)

研究者

发起方
Novartis Vaccines
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验